Final results from a phase 2 study of squalamine lactate ophthalmic solution 0.2 % (OHR-102) in the treatment of neovascular age-related macular degeneration (AMD) - Slakter, J S; Ciulla, T A; Elman, M J (Invest Ophthalmol Vis Sci, 2015)